Non-Alcoholic Fatty Liver Disease (NAFLD) Markets 2017 - Forecasts to 2027 for 11 Major Markets by Gender and 5-Year Age Cohort

Dublin, Nov. 30, 2017 -- The "Non-Alcoholic Fatty Liver Disease (NAFLD) Forecast in 11 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Non-alcoholic fatty liver disease (NAFLD) is the presence of hepatic steatosis in the absence of competing liver disease. It is a spectrum of liver disorders associated with steatosis, with no evidence of significant alcohol consumption. NAFLD develops in four main stages; Steatosis (simple fatty liver), Non-alcoholic steatohepatitis (NASH), Fibrosis and Cirrhosis.

Non-alcoholic steatohepatitis (NASH) is a more serious form of steatosis, due to the added inflammation. It is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis. This can progress to cirrhosis, liver failure and, more rarely, hepatocellular carcinoma.

This report provides the current prevalent population for Non-alcoholic fatty liver disease (NAFLD) across 11 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, Brazil, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight, several of the main symptoms and co-morbidities of NAFLD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Reasons to Buy:

• Able to quantify patient populations in global NAFLD market to target the development of future products, pricing strategies and launch plans
• Gain further insight into the prevalence of the subdivided types of NAFLD, including NASH, and identify patient segments with high potential
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
• Provide a level of understanding on the impact from specific co-morbid conditions on NAFLD prevalent population
• Identify sub-populations within NAFLD which require treatment
• Gain an understanding of the specific markets that have the largest number of NAFLD patients

Key Topics Covered:

1. Introduction
2. Nash
3. Cause of the Disease
4. Risk Factors & Prevention
5. Diagnosis of the Disease
6. - Stages of Fibrosis
7. Variation by Geography/Ethnicity
8. Disease Prognosis & Clinical Course
9. Key Comorbid Conditions/Features Associated With the Disease
10. Methodology for Quantification of Patient Numbers
11. Top-Line Prevalence of Nafld
12. Features of Nafld Patients
13. - Comorbid Conditions in Nafld Patients
14. Prevalence of Nash
15. - Grades of Fibrosis in Nash Patients
16. Abbreviations Used in the Report
17. Other Publications
18. Online Patient-Based Databases
19. Patient-Based Offering
20. Online Pricing Data and Platforms
21. References
22. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/zsj3hp/nonalcoholic

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Liver and Kidney Disorders Drugs